After reporting its TNF inhibitor reduced brain inflammation in Alzheimer’s disease patients, INmune will need to show that reducing inflammation translates into a cognitive benefit in a Phase II trial planned for next year. The study will be one of the first tests of the neuroinflammation theory as interest in the role of the immune […]

Inmune Bio Inc. CEO Raymond Tesi told BioWorld his firm is taking an “oncology-style” approach to Alzheimer’s disease (AD) as the firm tests next-generation tumor necrosis factor (TNF) inhibitor XPro-1595 against neuroinflammation. It’s working. Shares of the La Jolla-based firm (NASDAQ:INMB) closed at $15.75, up $6.90, or 78%, after the company reported interim findings from a phase Ib experiment that […]

Inmune Bio (INMB) stock skyrocketed to a record high Tuesday after the biotech company unveiled promising results for its Alzheimer’s treatment. Researchers tested the Alzheimer’s treatment in six patients over 12 weeks. At a lower dose, patients showed a 1.7% increase in brain inflammation. Patients who received a higher dose showed a 2.3% decrease. That compares with […]